AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06127069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic scaler
Description: debridement of periodontal pockets only with ultrasonic scaler
Study NCT05654103 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoAVF
Description: The device will be used according to manufactures instructions and medical facilities standard of care. EndoAVF has a high likelihood of requiring additional procedures that would not have been required if they had undergone surgAVF.
Study NCT05654103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgAVF
Description: The surgAAVF procedure will be done according to the medical facilities standard of care. SurgAVF can also require additional procedures to help with the fistula being useable.
Study NCT06367374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonrotoclax
Description: Participants receive zanubrutinib orally 160mg bid from start of Cycle 1, and in combination with sonrotoclax (SZ) from Cycle 4 onwards at increasing doses until 320mg daily target dose is reached and continuing for at least 12 cycles (each cycle is 28 days).~Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then.
Study NCT06367374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Participants receive zanubrutinib orally 160mg bid from start of Cycle 1,Participants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.~Participants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those with MRD-positive by then.
Study NCT05385016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking Skills
Description: This session will consist of a hands-on cooking demonstration in a demo kitchen. Skills addressed in this portion of the session will include proper kitchen utensil and appliance use, measuring dry and wet ingredients, following/reading a recipe, preparing ingredients, cooking a meal, etc. The participant will follow a visual recipe that provides a breakdown of each skill needed to complete each step of the recipe. Additionally, during the cooking session investigators will address nutrition topics related to food/kitchen safety, basic nutrition education (i.e., portion sizes, food groups, reading food labels, meal planning etc.) in a discussion format.
Study NCT05385016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: This session will consist of a group functional fitness class. Each session will include a warm-up (\~5 min) moderate-to-vigorous intensity aerobic and resistance exercise (\~20 min) and cool-down/stretching (\~5 min). Exercises may be accompanied by music and will include walking/jogging, dancing, imitating animal movements, vertical/horizontal jumps, squats, hurdles, walking on balance beam etc. Thera-Band, kettle bells, free weights, and medicine balls will be used during strength exercises for major muscle groups. These sessions will be led by certified personal trainers with experience in adaptive physical activity.
Study NCT05643066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg esketamine
Description: Esketamine 0.1 mg/kg was intravenously injected first.
Study NCT05643066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg esketamine
Description: Esketamine 0.2 mg/kg was intravenously injected first.
Study NCT05643066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline was intravenously injected first.
Study NCT05643066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 1 mg/kg was injected immediately. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
Study NCT04872686 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral and nasal spray by distilled water to control group
Description: Placebo comparator: Distilled Water Oral and Nasal spray will be provided by Distilled water to control group
Study NCT05831787 — intervention group
Intervention type: OTHER
Intervention: Patient Reported Outcomes
Description: Patients will be asked to complete baseline, 30-day, and 6-month clinical and patient reported outcome health surveys.
Study NCT05643066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol 1 mg/kg was injected immediately. Afterward, propofol 0.5 mg/kg was administered to maintain the target sedation level (MOAA/S of less than three).
Study NCT05003739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip arthroplasty with Logica Mirror femoral stem
Description: Total or partial hip arthroplasty with implant of Logica Mirror femoral stem
Study NCT04757675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine 0.3
Description: 0.3 μg/kg intravenous injection s-ketamin
Study NCT04757675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine 0.5
Description: 0.5 μg/kg intravenous injection s-ketamin
Study NCT04757675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine 2
Description: 2 μg/kg intranasal s-ketamin
Study NCT04757675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine 1+Dexmedetomidine 1
Description: 1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine
Study NCT05377320 — intervention group
Intervention type: OTHER
Intervention: Clinical Decision Aid
Description: The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24.
Study NCT05377320 — intervention group
Intervention type: OTHER
Intervention: Standard Care
Description: Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24.
Study NCT04757675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine 0.5 +Dexmedetomidine 2
Description: 0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine
Study NCT05570175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application RA joint protection and activity self-management program
Description: The intervention group received a mobile application RA joint protection and activity self-management program based on self-efficacy theory for 6 weeks. The program was based on self-efficacy theory and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
Study NCT05596110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TENS and KT
Description: TENS will be delivered using three E704SD TIMER TENS devices (or similar) through pairs of electrodes placed on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, KT (Kinesio Tex Gold) will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
Study NCT05596110 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: TENS and sham taping
Description: TENS will be delivered using three E704SD TIMER TENS devices (or similar) through pairs of electrodes placed on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
Study NCT05596110 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: KT and sham TENS
Description: KT (Kinesio Tex Gold) will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants. In addition, sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs.
Study NCT05596110 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham TENS and sham taping
Description: Sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
Study NCT04868695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
Description: 1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
Study NCT05904769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFELEAF Smartwatch
Description: Noninvasive wearable smartwatch/monitor that utilizes photoplethysmography (PPG) which is a set of measurements acquired from the light flashed from the back of the watch and measuring the intensity of the reflected light from the blood in the blood vessels just below the skin at the wrist. Provides a non-invasive method for measuring blood glucose as well as alternative method for measuring blood pressure, heart rate and rhythm, etc.
Study NCT06425172 — intervention group
Intervention type: DEVICE
Intervention: Cranial Remolding Orthosis
Description: A custom made FDA-approved cranial remolding orthosis will be retrofit with sensors used in the research.
Study NCT06275646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP layer
Description: platelet rich plasma layer was applied in addition to dartos flap
Study NCT06275646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dartos flap
Description: dartos flap alone was used
Study NCT06039878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bonding-Evoked Oxytocin
Description: Mother participates in bonding activity with infant at ages 1, 3, and 6 months
Study NCT06039878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Relieving Effects of Sucrose
Description: Researcher elicits distress in the infant (sequence of unswaddling, pacifier removal, and arm restraint), followed by delivery of oral sucrose in one condition and water in other condition
Study NCT06039878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hedonic Response to Sucrose
Description: Researcher gives infant opportunity to suck from two bottles, one containing sucrose and one plain water at infant ages 1, 3, and 6 months
Study NCT06039878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Typical versus Challenging Feeding-Social
Description: Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) regular size nipple versus smaller aperture nipple ('challenging') and (2) providing social interaction while feeding versus not.
Study NCT06039878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Compensation-Social
Description: Mother feeds infant on four counterbalanced days at infant ages 1, 3, and 6 months crossing two conditions: (1) offering a bottle feeding ad lib for 3 hours versus offering a bottle feeding every hour for 3 hours; (2) providing social interaction while feeding versus not.
Study NCT06039878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ability to Delay Gratification for Food in Infants-Social Task (ATDG-FIT-Social)
Description: When mother indicates infant is hungry, she presents the infant the bottle but withholds feeding for 5 minutes, feeds for one minute, withholds feeding for 30 seconds, and then resumes feeding. She does so under two conditions (providing social interaction during feeding versus not) on two counterbalanced days at infant ages 1, 3, and 6 months.
Study NCT05519839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: qNIV Vaccine with Matrix-M Adjuvant
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV vaccine given on Day 0 and Day 70 .
Study NCT05519839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: Intramuscular (deltoid) injections of Comparator influenza vaccine given on Day 0 and Day 70 (if applicable).
Study NCT05519839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIC Vaccine with Matrix-M Adjuvant
Description: Intramuscular (deltoid) injections of co-formulated mix of various doses and formulations of CIC Vaccine given on Day 0 and Day 70
Study NCT05090722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PureWick System
Description: The PureWick system consists of the external catheter, collection tubing, and collection canister with lid. It operates via a power cord that is plugged into the device outlet and the A/C power outlet.
Study NCT05519839 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Intramuscular (deltoid) injection of placebo given on Day 70.
Study NCT05519839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of SARS-CoV-2 rS vaccine given on Day 0 and Day 70 .
Study NCT06046313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine for Injection
Description: 6mg/m2, ivgtt qd d1-10
Study NCT06046313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VENCLYXTO
Description: 100mg p.o.d1, 200mg p.o.d2, 400mg p.o.d3-21,adjust by blood concentration
Study NCT05228613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 protein subunit recombinant vaccine
Description: candidate vaccine manufactured by PT. Bio Farma
Study NCT05228613 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 inactivated vaccine
Description: active control manufactured by Sinovac Life Sciences Co.Ltd
Study NCT06475131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B16D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT06434532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: v-Care Online Game
Description: A regular 2 hours traditional learning mode session - case study session and 2-hour online game session with peer-led discussion and interprofessional project submission. This spreads in 3 weeks interval
Study NCT06434532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case-based online discussion
Description: A 2-hour traditional learning mode session with online peer-led discussion and submission of an interprofessional worksheet as an assignment
Study NCT04779645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REMD-477
Description: 12-Week, once weekly subcutaneous injection with 70mg REMD-477
Study NCT04779645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12-Week, once weekly subcutaneous injection with placebo
Study NCT06402500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icon Infiltrant
Description: White spot lesions are treated with the resin ICON (DMG, NJ, US) for masking their color. The mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
Study NCT06402500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bioactive infiltrant
Description: White spot lesions are treated with HI-Bond universal bioactive resin (MEDICLUS, south Korea) for masking their color. Mineral content will be measured in the lesion at baseline and after one month Quantitative light-induced fluorescence QLF.
Study NCT06211803 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Positron-Emission Tomography Imaging
Description: Examination of radiation distribution in the patient brain and body after completing a routine examination on a PET diagnostic device. J-PET prototype tests will be carried out in patients who have undergone a classic PET examination after administration of \[18F\]FDG), \[68Ga\]Ga-PSMA or \[68Ga\]Ga-DOTATATE). The duration of the additional exam will be approximately 20 minutes.
Study NCT04509076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP iT! (plus usual PrEP care)
Description: The PrEP iT! intervention is a mobile-optimized website, with the following components:~* PrEP Adherence, PrEP Appointment, and Sexual Activity Self-Monitoring~* Tailored feedback on PrEP adherence/non-adherence~* PrEP and sexual health information tailored for YMSM~* Text message reminders for PrEP adherence and healthcare appointments~* An ask the expert feature
Study NCT04509076 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual PrEP care
Description: Clinic visits every 3 months in the initial period following PrEP initiation, including HIV/STI screening and laboratory toxicity testing
Study NCT05228223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular monitoring
Description: TOF monitoring
Study NCT05228223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reverse of NMB with sugammadex
Description: Patients reversed with Sugammadex 2mg/kg after TOF count is 1-2.
Study NCT05228223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reverse of NMB with Sugammadex and neostigmin low dose
Description: Patients reversed with Sugammadex 1mg/kg + Neostigmin 0.02 mg/kg
Study NCT05228223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reverse of NMB with Sugammadex and neostigmin high dose
Description: patients reversed with sugammadex 1.5 mg/kg + Neostigmin 0.02 mg/kg
Study NCT05908240 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care Coordinator Model
Description: A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.
Study NCT06574282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Second alkaline phosphatase measurement
Description: (1-4 weeks after the 1st measurement)
Study NCT05106491 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Synchronized Cardiac Support with the icor kit
Description: Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).
Study NCT05611710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo, with visually matched clear syringes~* Adults (≥16 years) and children (12-16 years, > 50Kg) will receive 2 syringes of placebo via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive no more than 1 syringe of placebo via IV route, twice daily for 4 days
Study NCT05611710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Drug: Anakinra~* Adults (≥16 years) and children (12-16 years, > 50Kg) will receive 200mg of anakinra (2 syringes) via IV route, twice daily for 4 days~* Children (12-16 years, \< 50Kg) will receive 2mg/Kg of anakinra via IV route, twice daily for 4 days (no more than 1 syringe of anakinra, twice daily for 4 days)
Study NCT05794100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute intake of one of the products (active comparator 1 to 9) or Placebo comparator
Description: One pack of each product (1 to 10) will be consumed on a separate occasion
Study NCT05794100 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acute intake of one of the products (active comparator 1 to 9) or Placebo comparator
Description: One pack of each product (1 to 10) will be consumed on a separate occasion
Study NCT05699343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: InterOss Collagen (Bone xenograft) and InterOss Collagen Guide (Collagen membrane)
Description: Group will receive InterOss Collagen and InterOss Collagen Guide during surgical intervention visit.
Study NCT05699343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: InterOss Collagen (Bone xenograft)
Description: Group will only receive InterOss Collagen during surgical intervention visit.
Study NCT05575882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin hydration
Description: Skin hydration outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
Study NCT05575882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Skin hydration
Description: Skin hydration outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
Study NCT05575882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barrier function measurement
Description: TEWL measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
Study NCT05575882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Barrier function measurement
Description: TEWL measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.